Bayer eyes label expansion on Phase III non-diabetic CKD win
If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who have a non-diabetic form of the disease.
Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
YolTech Therapeutics gains FDA approval for Phase II/III AATD trial
J&J reports positive data for Erda-iDRS in bladder cancer
Parkinson’s research reaches “pivotal” stage, but barriers remain
Analysis
View More
Themes
View MoreCinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View more
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Oncology trial systems debut at SCOPE 2026 as AI adoption accelerates
Biorce secures $52.5m in Series A to expand AI clinical trial tech
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Patient-centric approaches thrive on wearables and remote access in trials